Hosted by Nessan Bermingham PhD · EN-US · 43 episodes
Established thought leaders with verified media credentials.
Between the Biotech Waves—discussing recent developments and market dynamics impacting the biotech sector.
Nessan Bermingham PhD hosts Between the Biotech Waves, a science show with 43 episodes published.
Today’s episode features a remarkable leader in the field of gene therapy, Dr. Bobby Gaspar. With over 25 years of experience as a physician and scientist, Bobby has played a pivotal role in redefining treatment options
I am thrilled to welcome Steve Paul to Between the Biotech Waves. With nearly 50 years of experience as a physician-scientist, Steve has made significant contributions to the fields of neuroscience, molecular neuropharma
Today, I are excited to welcome Kent Rogers, the Chief Executive Officer of EveryONE Medicines. Kent brings a wealth of experience to his new role, having held executive leadership positions at renowned pharmaceutical co
Sound Bite with Bill Hicks looking at the market and financing in real time.
Welcome to a Between the Biotech Waves sound bite , a short podcast to provide insight into the rapidly changing biotech environment - I am pleased to welcome Paul Matteis Managing Director, Head of Therapeutics Equity R
In this episode, I am thrilled to welcome Dan Lynch, an Executive Venture Partner at Google Ventures and a seasoned leader in the biotechnology sector. Since joining GV in 2021, Dan has partnered with life sciences CEOs
In today's episode, I am honored to welcome Stanley Crooke, the founder and CEO of Ionis Pharmaceuticals the first and leading antisense oligonucleotide biotech and founder, CEO and Chair of N-Lorem, a not for profit ent
Welcome to ‘Between the Biotech Waves,’ the podcast where we navigate the dynamic world of biotechnology and explore the minds driving its innovation. I’m your host, Nessan Bermingham, and today, we have a true visionary
Now that JPM '25 is behind us, where the weather was great but the mood was somber, back to podcasting! Welcome back to 'Between the Biotech Waves,' the podcast where we explore the frontiers of biotechnology and the rem
Welcome back to Between the Biotech Waves. I am sorry for the lack of episodes over the past few months, unfortunately life threw me a curve ball that I have been taking care of but now back and ready to go! Today it giv
Today we have an unusual (& long) podcast where we talk to key members of the Triplet Therapeutics management team. Triplet was founded to develop antisense oligonucleotides targeting the DNA damage response pathway that
Today I am talking to Eliot Forster xCEO of F-star Therapeutics. Eliot was at helm of the company as they reversed merged into Springbank Pharmaceuticals & through the recently announced acquisition by Sino Biopharma, a
Today we are talking to Barry Greene, CEO of Sage Therapeutics. Barry has had an amazing career spanning over 30 years in the biotech industry. Prior to Sage Barry was President of Alnylam shepherding it with John throug
Today we are talking to Tim Yu. Tim is attending physician at the division of genetics and genomics at Boston Children’s Hospital and assoc prof of Pediatrics at Harvard Medical School. The scope of work that Tim does is
Today we are talking to Rachel Meyers. Rachel was most recently the CSO of Faze Medicines a company she launched with TRV to focus on the regulation of biomolecular condensates to treat disease. Prior to Faze she was an
Today we are talking to Joel Marcus. He has shaped the life sciences industry through ARE from the buildings we use to venture and fund investing. His impact can be directly seen in major cities across the US from Boston
Today we are talking to Aofie Brennan, president and CEO of Synlogic. Aoife was trained as a doctor at Trinity College Dublin following which she moved to the US. After completing her postdoctoral research at Beth Israel
Today we are talking to Drew Weissman. Drew is the Roberts Family Professor in Vaccine Research at Perelman School of Medicine and Director of the Penn Institute for RNA Innovation at the University of Pennsylvania. Drew
Today we are talking to Rodolphe Barrangou. Rodolphe is the Todd R Klaenhammer Distinguished Professor at NC State University. He is a scientist entrepreneur who has co-founded a multitude of biotech companies around CRI
I am delighted to welcome back John Hoffman to Between the Biotech Waves. John is managing director & head of healthcare equity capital markets at Credit Suisse. In mid 2022 John joined the podcast to discuss the market
Bill Hicks
co-chair of the life sciences practice · Mintz
1 appearance on this show
Peter Barrett
Food Writer, Photographer, and Artist · SMBC Aviation Capital
1 appearance on this show
Mike Curtis
President and CEO · Dallas Morning News
1 appearance on this show
Dr Aoife Brennan
President and CEO · Climb Bio
1 appearance on this show
Dr. Drew Weissman
Roberts Family Professor in Vaccine Research at Perelman School of Medicine
1 appearance on this show
Katalin Kariko
Nobel Prize-Winning Scientist
1 appearance on this show
John Hoffman
managing director & head of healthcare equity capital markets · Only Murders in the Building
1 appearance on this show
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch Between the Biotech Waves, visit https://www.buzzsprout.com/1992308 for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent science coverage.
Between the Biotech Waves is hosted by Nessan Bermingham PhD. The show is categorised under science (life) and has published 43 episodes.
Between the Biotech Waves has published 43 episodes.
Between the Biotech Waves regularly covers science, life, business. It sits in the science category, with a life focus.
Between the Biotech Waves is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Between the Biotech Waves hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Between the Biotech Waves average 57 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Between the Biotech Waves's guest bar at 81/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched yesterday.
